Novel immunotherapeutic drugs for the treatment of lung cancer.
Curr Opin Oncol
; 34(1): 89-94, 2022 Jan 01.
Article
em En
| MEDLINE
| ID: mdl-34636350
ABSTRACT
PURPOSE OF REVIEW Cancer cells evade immune surveillance partly due to the immunosuppressive features of the tumor microenvironment (TME). Currently approved immuno-oncology drugs for the treatment of lung cancer are aimed to inhibit immune checkpoints, such as programmed death protein-1 (PD-1), PD ligand-1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4. Despite these, researchers are currently racing to create the optimal cancer immunotherapy treatments. RECENT FINDINGS:
Novel immunotherapeutic drugs mainly act on activated immune cells and exert their therapeutic effects by enhancing antitumor responses. In this article, we review new therapies for the treatment of lung cancer that enhance T cell priming, remove coinhibitory signals, supply costimulatory signals and condition the TME.SUMMARY:
As more immunotherapeutic targets are in studies, designing multimodal strategies to provide greater efficacy with lower toxicity will be necessary.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Imunoterapia
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article